



FIG. 1b



FIG. 1a




FIG. 1c





FIG. 1d

3/17






FIG. 2e

FIG. 2d




FIG. 3




FIG. 4

7/17





FIG. 5



**FIG. 6A**

L1210 TARGETS(T)

☐ E:T RATIO 60  
☐ E:T RATIO 30  
☐ E:T RATIO 15  
☒ E:T RATIO 7.5




FIG. 6B

10/17




FIG. 7




FIG. 8a




FIG. 8b




FIG.9

Fluorescence Intensity  
(log Scale)






FIG.10


Insulin + hybridoma




allo MLR Proliferation




allo MLR IL-2



allo MLR +/- anti B7





- A**
- ▲ L1210+P815 (7X)
  - ▼ L1210+HY38/GM-CSF (7X)
  - ◆ P815+P815 (7X)
  - P815+HY38/GM-CSF (3X)
  - P815+HY38/GM-CSF (7X)
- B**
- ▼ untreated mice + P815 ascite
  - surviving mice treated with HY38/GM-CSF (7X) + P815 ascite
  - surviving mice treated with HY38/GM-CSF (3X) + P815 ascite

